Culture

Today, Parabilis Medicines announced a strategic research collaboration with Regeneron Pharmaceuticals to discover and develop multiple therapeutic candidates based on our Helicon peptide platform, with a particular focus on Antibody-Helicon Conjugates (AHCs), a novel class of therapeutics designed to target challenging and historically “undruggable” proteins.

The collaboration combines Regeneron’s capabilities in genetics, antibody engineering, and biologics development with Parabilis’s expertise in developing Helicons capable of engaging intracellular targets not well suited to traditional small molecule binding. The collaboration is designed to explore the use of Helicons both as standalone therapies and as part of AHCs across multiple therapeutic areas.

Today, we are thrilled to welcome Alan M. Sebulsky to Parabilis’s Board of Directors.

Through a decades-long career in biopharmaceutical investing, portfolio strategy and board leadership, Alan brings a unique perspective to support our pipeline and the application of our Helicon platform.

Learn more in today’s release: https://lnkd.in/ex7rR48z

Creating extraordinary medicines starts with an extraordinary team. Today, we’re excited to welcome a new leader to our executive team and celebrate a key leadership promotion at Parabilis.

Helen Ho joins us as Chief Business and Strategy Officer, bringing deep expertise across corporate strategy and business development, including executing high-impact partnerships and transactions across biotech companies at multiple stages of growth. Thomas Kotarakos has been promoted to Chief Financial Officer. Over more than four years with Parabilis, Tom has played a central role in building our financial strategy and infrastructure, including leading our recent oversubscribed $305 million Series F financing.

News alert 🚨: Our lead investigational Helicon peptide, zolucatetide, has received FDA Orphan Drug Designation for the treatment of desmoid tumors. Zolucatetide was also granted FDA Fast Track Designation in desmoid tumors in 2025.

Zolucatetide is a first-in-class inhibitor of the Wnt/β-catenin:TCF pathway, the fundamental driver of desmoid tumor growth — which, until now, has been considered “undruggable.” Desmoid tumors are rare locally invasive soft-tissue tumors that form in the connective tissues. These tumors can be aggressive and recurrent, often causing chronic and significant pain, limited mobility, disfigurement and organ dysfunction, and no existing therapies target the underlying biology of the disease.

At this week’s International Society for Gastrointestinal Hereditary Tumours (InSiGHT) Biennial Meeting in Singapore, we presented preliminary clinical evidence supporting the potential of our lead investigational Helicon peptide, zolucatetide (previously FOG-001) – the first and only direct inhibitor of the elusive β-catenin:TCF interaction – in patients with familial adenomatous polyposis (FAP).

FAP is a rare inherited disorder that leads to the development of hundreds to thousands of precancerous colorectal polyps and near-inevitable progression to colorectal cancer if left untreated.

Today, we are excited to share that we’ve closed an oversubscribed $305 million Series F financing, co-led by RA Capital Management, Fidelity Management & Research Company and Janus Henderson Investors and strongly supported by our already strong syndicate of investors.

On the heels of the clinical data our team shared this fall at multiple medical meetings demonstrating we’ve “drugged the undruggable,” this financing is a deeply important reinforcement of the value and therapeutic potential of our Helicon™ medicines.

📣 Exciting update: The FDA has granted Fast Track designation to our lead investigational Helicon peptide, FOG-001, for the treatment of desmoid tumors— recognizing the significant unmet need in this disease area and the potential of this first-in-class therapy to transform patient care.

Desmoid tumors are rare, locally invasive soft-tissue tumors that can cause severe pain, immobility, and organ dysfunction. Despite their impact on quality of life, there are no approved therapies that directly target the underlying disease biology — driven by dysregulated Wnt/β-catenin signaling.

New data alert!  🔔

This week at the AACR–NCI–EORTC “Triple” Meeting, we shared additional data showing that FOG-001 has demonstrated early clinical activity across multiple Wnt/β-catenin–driven tumors, reinforcing its potential to address both low-complexity and more complex rare and common solid tumors through both monotherapy and combination approaches.

A defining moment for Parabilis, for science, and for patients.

At the ESMO Congress, we shared the first-ever clinical evidence that our lead investigational therapy, FOG-001, can directly inhibit the β-catenin:TCF complex, a critical downstream node in the Wnt/β-catenin pathway.

We’ve been on-site at #ASCO25 connecting with our oncology colleagues and celebrating the great progress happening across cancer research. There was a great reception to our trial-in-progress poster on the Phase 1/2 clinical trial of FOG-001, the first and only direct inhibitor of the β-catenin:TCF4 interaction — a promising mechanism being evaluated for #desmoid tumors, #colorectalcancer, and other Wnt pathway-driven tumors.

At #AACR25, we presented first-in-industry proof of targeted degradation of the transcription factor ERG — a notorious difficult-to-drug and high-value target in prostate cancer, implicated in 40-50% of all cases. First-generation degraders have failed to effectively target ERG but our Helicon technology changes that.

At Parabilis, we’re united by an ambitious mission of #CreatingExtraordinaryMedicines. Achieving that goal takes an extraordinary team – one that boldly innovates, seamlessly collaborates, and makes each other better by embracing different perspectives and challenging each other to create the best solutions and outcomes.

Today, on International Day of Women and Girls in Science, we celebrate the women in Research and Development at Parabilis who are driving our progress toward #CreatingExtraordinaryMedicines.

Hear from some of the incredible women on our team about what inspires them to push the boundaries of what’s possible in science and medicine.

Hot off the press at #JPM25! Today Parabilis CEO Mathai Mammen, M.D., Ph.D. presented updates on the clinical progress of our β-catenin:TCF4 inhibitor, FOG-001, and our wider Helicon portfolio.

Early clinical data on FOG-001 (the first and only direct inhibitor of β-catenin:TCF4) demonstrate monotherapy antitumor activity and in-tumor target engagement — confirming Helicons’ ability to target proteins previously considered undruggable in patients.

This holiday season, Parabilis served up fun and a little friendly competition at our annual winter outing and holiday celebration, which included a spirited pickleball tournament with 36 teams, new branded swag to ring in the new year, and plenty of opportunities to come together as a team.

To celebrate our new name and vision as a company, we created pocket-sized images personifying Parabilis’ spirit and values and asked our team to take one along on their next adventure.

Over the next few weeks, employees snapped photos of their Parabilis “spaceships” while traveling to Istanbul, Penn State Stadium, Nevada mountains, Munich Hofbräuhaus, Barcelona, Turks and Caicos, Montreal, Jamaica, the Palace Theater in Ohio, Brooklyn Bridge, and outer space (or as close as we could get).

We’re thrilled to share that Parabilis Medicines has been named the winner in the Late-Stage Biotech category at the 2024 BostInno Fire Awards!

We’re immensely honored to represent the innovative spark that powers the #Boston-area biotech ecosystem. 2024 has been an incredible year for us, from the growth of our team, progressing our programs forward, our Series E financing and a radiopharmaceutical collaboration to the advances in our data science-enabled platform.

We were thrilled to recently welcome Mohammed AlQuraishi from Columbia University to Parabilis for a discussion about the state of the art in computational protein design today. Dr. AlQuraishi is a world expert in systems biology who recently played a central role in the development of OpenFold, an open-source AI model for predicting the 3D structures of proteins from their sequences.

We’re developing medicines to address the most pressing needs in cancer treatment today. But we know that individuals and families face many kinds of hardship after a cancer diagnosis that extend far beyond the hospital or clinic: disruption to daily life, feelings of isolation, and logistical and financial burdens from treatment and care. For that reason, we felt honored recently to volunteer at the American Cancer Society Hope Lodge in Boston, a place that offers cancer patients and their caregivers a free ‘home away from home’ during their treatment.

We were honored to host Eric Schadt, a leading figure in computational biology and precision medicine, at our offices recently. In his current roles as CSO of Pathos, Dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai, and across the rest of his distinguished career, Dr. Schadt has driven innovation in the use of data science to pair precise patient populations with more targeted interventions — something we’re passionately advancing here at FogPharma as well.

This week, #TeamParabilis came together for our Haunted Fall Carnival, an afternoon filled with festive treats and carnival games, like Halloween Bingo and a spirited team relay. Whether at work or at play, our team brings their all – especially when a costume contest is involved.

We were very grateful to have Regina Barzilay — one of the world’s leading AI/machine learning researchers and a Distinguished Professor for AI and Health at CSAIL MIT — join us recently to discuss the fast-evolving landscape of machine learning in drug discovery. Dr. Barzilay presented some of her own pioneering work in building AI models to optimize small-molecule drug design and protein engineering.